Home World News FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer World News FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 863 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan January 16, 2025 Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... March 6, 2024 New tool to tackle gaps in public’s knowledge of blood cancer... July 14, 2023 Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Load more HOT NEWS Scientists Find Genetic Changes Linked to Cancer in Children European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on... 4-Year-Old Boy Calls Police To Tell Them About His Toys, Cop...
